User profiles for C. M. Hogaboam
Cory HogaboamCedars-Sinai Medical Center Verified email at cshs.org Cited by 32570 |
The link between fungi and severe asthma: a summary of the evidence
…, BR O'driscoll, CM Hogaboam… - European …, 2006 - Eur Respiratory Soc
There is current evidence to demonstrate a close association between fungal sensitisation
and asthma severity. Whether such an association is causal remains to be confirmed, but this …
and asthma severity. Whether such an association is causal remains to be confirmed, but this …
Murine models of pulmonary fibrosis
BB Moore, CM Hogaboam - American Journal of …, 2008 - journals.physiology.org
Human pulmonary fibrosis is characterized by alveolar epithelial cell injury, areas of type II
cell hyperplasia, accumulation of fibroblasts and myofibroblasts, and the deposition of …
cell hyperplasia, accumulation of fibroblasts and myofibroblasts, and the deposition of …
Animal models of fibrotic lung disease
…, K Raghavendran, CM Hogaboam - American journal of …, 2013 - atsjournals.org
Interstitial lung fibrosis can develop as a consequence of occupational or medical exposure,
as a result of genetic defects, and after trauma or acute lung injury leading to …
as a result of genetic defects, and after trauma or acute lung injury leading to …
TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events
…, PM Lincoln, NW Lukacs, CM Hogaboam… - The Journal of …, 2008 - rupress.org
Ligands from dying cells are a source of Toll-like receptor (TLR) activating agents. Although
TLR3 is known to respond to RNA from necrotic cells, the relative importance of this …
TLR3 is known to respond to RNA from necrotic cells, the relative importance of this …
Epigenetic regulation of the alternatively activated macrophage phenotype
Alternatively activated (M2) macrophages play critical roles in diverse chronic diseases,
including parasite infections, cancer, and allergic responses. However, little is known about the …
including parasite infections, cancer, and allergic responses. However, little is known about the …
TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P
…, N van Rooijen, JA Elias, CM Hogaboam… - The international journal …, 2011 - Elsevier
The pleiotropic growth factor TGFβ 1 promotes many of the pathogenic mechanisms observed
in lung fibrosis and airway remodeling, such as aberrant extracellular matrix deposition …
in lung fibrosis and airway remodeling, such as aberrant extracellular matrix deposition …
IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense
ML Steinhauser, CM Hogaboam, SL Kunkel… - The Journal of …, 1999 - journals.aai.org
To explore the mechanism of immunosuppression associated with sepsis, we developed a
murine model of sepsis-induced Pseudomonas aeruginosa pneumonia. CD-1 mice …
murine model of sepsis-induced Pseudomonas aeruginosa pneumonia. CD-1 mice …
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10)
…, V Stambolic, TW Mak, CM Hogaboam… - American journal of …, 2006 - atsjournals.org
Rationale: Myofibroblasts are primary effector cells in idiopathic pulmonary fibrosis (IPF).
Defining mechanisms of myofibroblast differentiation may be critical to the development of …
Defining mechanisms of myofibroblast differentiation may be critical to the development of …
PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis
…, SR Gangireddy, CM Hogaboam… - … of Physiology-Lung …, 2008 - journals.physiology.org
Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in
excessive extracellular matrix accumulation and anatomic remodeling. Current therapies for this …
excessive extracellular matrix accumulation and anatomic remodeling. Current therapies for this …
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report
…, CA Henke, E Herzog, CM Hogaboam… - American journal of …, 2014 - atsjournals.org
The median survival of patients with idiopathic pulmonary fibrosis (IPF) continues to be
approximately 3 years from the time of diagnosis, underscoring the lack of effective medical …
approximately 3 years from the time of diagnosis, underscoring the lack of effective medical …